Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Given Hold Rating at Canaccord Genuity Group

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Get Free Report)'s stock had its "hold" rating reaffirmed by investment analysts at Canaccord Genuity Group in a note issued to investors on Wednesday,Benzinga reports. They currently have a $107.00 price target on the stock. Canaccord Genuity Group's price objective indicates a potential upside of 2.04% from the company's previous close.

Other equities research analysts have also issued research reports about the stock. HC Wainwright raised their price target on shares of Verona Pharma PLC American Depositary Share from $85.00 to $90.00 and gave the company a "buy" rating in a research note on Monday, June 2nd. Cowen initiated coverage on shares of Verona Pharma PLC American Depositary Share in a research note on Monday, April 28th. They issued a "buy" rating on the stock. Wolfe Research started coverage on shares of Verona Pharma PLC American Depositary Share in a research note on Tuesday, July 1st. They issued an "outperform" rating and a $170.00 price target on the stock. TD Cowen began coverage on shares of Verona Pharma PLC American Depositary Share in a report on Monday, April 28th. They issued a "buy" rating and a $100.00 price objective for the company. Finally, Piper Sandler set a $160.00 price objective on shares of Verona Pharma PLC American Depositary Share and gave the company an "overweight" rating in a research note on Monday, June 23rd. Four equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $107.45.

Verona Pharma PLC American Depositary Share Stock Performance

VRNA traded up $0.09 on Wednesday, hitting $104.86. 5,725,457 shares of the company's stock were exchanged, compared to its average volume of 1,531,992. The firm has a market cap of $8.50 billion, a PE ratio of -52.41 and a beta of 0.24. Verona Pharma PLC American Depositary Share has a twelve month low of $16.91 and a twelve month high of $104.95. The stock has a fifty day moving average of $82.60 and a two-hundred day moving average of $66.84. The company has a current ratio of 8.86, a quick ratio of 8.73 and a debt-to-equity ratio of 1.07.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The company reported $0.27 earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.49. The business had revenue of $98.65 million for the quarter, compared to analyst estimates of $41.47 million. On average, research analysts anticipate that Verona Pharma PLC American Depositary Share will post -1.95 earnings per share for the current fiscal year.

Insider Buying and Selling at Verona Pharma PLC American Depositary Share

In related news, General Counsel Andrew Fisher sold 80,000 shares of the firm's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $11.53, for a total transaction of $922,400.00. Following the completion of the sale, the general counsel directly owned 359,999 shares in the company, valued at approximately $4,150,788.47. This trade represents a 18.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO David Zaccardelli sold 400,000 shares of the firm's stock in a transaction that occurred on Wednesday, June 11th. The stock was sold at an average price of $11.40, for a total transaction of $4,560,000.00. Following the sale, the chief executive officer owned 13,190,168 shares of the company's stock, valued at $150,367,915.20. The trade was a 2.94% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,965,800 shares of company stock valued at $20,056,881. 4.80% of the stock is currently owned by corporate insiders.

Institutional Trading of Verona Pharma PLC American Depositary Share

Large investors have recently added to or reduced their stakes in the business. NBC Securities Inc. bought a new stake in Verona Pharma PLC American Depositary Share during the first quarter worth approximately $34,000. Geneos Wealth Management Inc. boosted its holdings in Verona Pharma PLC American Depositary Share by 44.2% during the first quarter. Geneos Wealth Management Inc. now owns 630 shares of the company's stock worth $40,000 after buying an additional 193 shares in the last quarter. Vermillion Wealth Management Inc. acquired a new position in Verona Pharma PLC American Depositary Share in the 4th quarter worth approximately $46,000. Acadian Asset Management LLC acquired a new position in Verona Pharma PLC American Depositary Share in the 1st quarter worth approximately $48,000. Finally, NewEdge Advisors LLC acquired a new position in Verona Pharma PLC American Depositary Share in the 1st quarter worth approximately $58,000. 85.88% of the stock is currently owned by institutional investors.

Verona Pharma PLC American Depositary Share Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.